| 1 |
Kietaibl S, Ahmed A, Afshari A, Albaladejo P, Aldecoa C, Barauskas G, De Robertis E, Faraoni D, Filipescu DC, Fries D, Godier A, Haas T, Jacob M, Lancé MD, Llau JV, Meier J, Molnar Z, Mora L, Rahe-Meyer N, Samama CM, Scarlatescu E, Schlimp C, Wikkelsø AJ, Zacharowski K. Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care: Second update 2022. Eur J Anaesthesiol 2023;40:226-304. [PMID: 36855941 DOI: 10.1097/EJA.0000000000001803] [Reference Citation Analysis]
|
| 2 |
Yoshida H, Ohki T, Kanezaki M, Teratani T, Sato S, Obi S, Sato T, Akamatsu M, Uchino K, Taniguchi H. Safe radiofrequency ablation for low platelet count patients with a novel platelet count raising drug (lusutrombopag): Prospective Observational Study.. [DOI: 10.21203/rs.3.rs-2423711/v1] [Reference Citation Analysis]
|
| 3 |
Lisman T. Bleeding and thrombosis in cirrhosis. Cardio-Hepatology 2023. [DOI: 10.1016/b978-0-12-817394-7.00010-3] [Reference Citation Analysis]
|
| 4 |
Lim HI, Cuker A. Thrombocytopenia and liver disease: pathophysiology and periprocedural management. Hematology Am Soc Hematol Educ Program 2022;2022:296-302. [PMID: 36485111 DOI: 10.1182/hematology.2022000408] [Reference Citation Analysis]
|
| 5 |
Ding JN, Feng TT, Sun W, Cai XY, Zhang Y, Zhao WF. Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study. World J Gastrointest Surg 2022; 14(11): 1260-1271 [DOI: 10.4240/wjgs.v14.i11.1260] [Reference Citation Analysis]
|
| 6 |
Mücke MM, Bruns T, Canbay A, Matzdorff A, Tacke F, Tiede A, Trebicka J, Wedemeyer H, Zacharowski K, Zeuzem S, Lange CM. Einsatz von Thrombopoetin-Rezeptor-Agonisten (TPO-RA) vor invasiven Eingriffen bei Patienten mit Leberzirrhose. Z Gastroenterol 2022. [DOI: 10.1055/a-1934-1867] [Reference Citation Analysis]
|
| 7 |
Biolato M, Vitale F, Marrone G, Miele L, Grieco A. A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series. Medicine (Baltimore) 2022;101:e31429. [PMID: 36343065 DOI: 10.1097/MD.0000000000031429] [Reference Citation Analysis]
|
| 8 |
Maevskaya MV, Zharkova MS, Ivashkin VT, Bessonova EN, Geyvandova NI, Kitsenko EA, Korochanskaya NV, Kurkina IA, Melikyan AL, Morozov VG, Khoronko YV. Diagnosis of disorders in the coagulation system, assessment of the risk of hemorrhagic complications in severe cirrhosis/liver diseases according to global screening tests of the hemostasis system and principles for their correction: guidelines. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-15-70-82] [Reference Citation Analysis]
|
| 9 |
Gallo P, Terracciani F, Di Pasquale G, Esposito M, Picardi A, Vespasiani-Gentilucci U. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures. World J Gastroenterol 2022; 28(30): 4061-4074 [DOI: 10.3748/wjg.v28.i30.4061] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Flamm SL, Peck-Radosavljevic M, Fukuhara T, Bentley R, Katsube T, Ochiai T, Kano T, Tsukimura E, Sasaki R, Osaki Y. Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child-Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance. Adv Ther 2022. [PMID: 35904722 DOI: 10.1007/s12325-022-02237-8] [Reference Citation Analysis]
|
| 11 |
Orme ME, Bentley R, Marcella S, Peck-Radosavljevic M, Perard R, Wedemeyer H, Yoshiji H, Agarwal K, Dusheiko G. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures. Adv Ther 2022. [PMID: 35836089 DOI: 10.1007/s12325-022-02235-w] [Reference Citation Analysis]
|
| 12 |
. Stellungnahme der DGVS zur Nutzenbewertung des GBA zum Wirkstoff Lusutrombopag (Thrombozytopenie bei chronischer Lebererkrankung). Z Gastroenterol 2022;60:1050-1. [DOI: 10.1055/a-1851-7778] [Reference Citation Analysis]
|
| 13 |
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol 2022;76:1151-84. [PMID: 35300861 DOI: 10.1016/j.jhep.2021.09.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 37.0] [Reference Citation Analysis]
|
| 14 |
Feng R, Liu Y, Zhu XL, Zhai WY, He Y, Fu HX, Jiang Q, Jiang H, Lu J, Liu H, Wang JW, Wang H, Xie YD, Ma H, Huang XJ, Zhang XH. Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B-related cirrhosis: Multicentre real-world observational study. J Viral Hepat 2022;29:306-16. [PMID: 35152507 DOI: 10.1111/jvh.13655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Eguchi Y, Takahashi H, Mappa S, Santagostino E. Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia. Hepatol Res 2022;52:371-80. [PMID: 35134259 DOI: 10.1111/hepr.13755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Czajka P, Przybyłkowski A, Nowak A, Postula M, Wolska M, Mirowska-Guzel D, Czlonkowska A, Eyileten C. Antiplatelet drugs and liver fibrosis. Platelets 2022;33:219-28. [PMID: 33577391 DOI: 10.1080/09537104.2021.1883574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 17 |
Yoshida M, Tateishi R, Hiroi S, Hongo Y, Fujiwara M, Kitanishi Y, Iwasaki K, Takeshima T, Igarashi A. Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease. Adv Ther 2022;39:379-90. [PMID: 34748184 DOI: 10.1007/s12325-021-01965-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 18 |
Tanaka K, Baba T, Yoshida M, Iguchi M, Sonoyama T, Fukuhara T, Kano T. Relationship between baseline clinical characteristics and efficacy of lusutrombopag in thrombocytopenic patients with chronic liver disease: post hoc analysis of two placebo-controlled phase 3 trials. Curr Med Res Opin 2021;:1-8. [PMID: 34904508 DOI: 10.1080/03007995.2021.2012964] [Reference Citation Analysis]
|
| 19 |
Yoshiji H, Ueno Y, Kurosaki M, Torimura T, Hatano E, Yatsuhashi H, Yamakado K. Treatment algorithm for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures. Hepatol Res 2021;51:1181-95. [PMID: 34555262 DOI: 10.1111/hepr.13715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Flisiak R, Antonov K, Drastich P, Jarcuska P, Maevskaya M, Makara M, Puljiz Ž, Štabuc B, Trifan A. Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures. J Clin Med 2021;10:5419. [PMID: 34830701 DOI: 10.3390/jcm10225419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 21 |
Nguyen G, Lejeune M, Crichi B, Frere C. Hemostasis testing in patients with liver dysfunction: Advantages and caveats. World J Gastroenterol 2021; 27(42): 7285-7298 [PMID: 34876789 DOI: 10.3748/wjg.v27.i42.7285] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 22 |
O'Shea RS, Davitkov P, Ko CW, Rajasekhar A, Su GL, Sultan S, Allen AM, Falck-Ytter Y. AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. Gastroenterology 2021;161:1615-1627.e1. [PMID: 34579936 DOI: 10.1053/j.gastro.2021.08.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 23 |
Primignani M, Tosetti G, Tripodi A. Implementing pre-procedural thrombopoietin receptor agonists in cirrhotic patients with severe thrombocytopenia: Indiscriminate, selective or unneeded? Dig Liver Dis 2021;53:1394-5. [PMID: 34446353 DOI: 10.1016/j.dld.2021.08.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 24 |
Intagliata NM, Davitkov P, Allen AM, Falck-Ytter YT, Stine JG. AGA Technical Review on Coagulation in Cirrhosis. Gastroenterology 2021;161:1630-56. [PMID: 34579937 DOI: 10.1053/j.gastro.2021.09.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 25 |
Rose PD, Au M, Woodman RJ, Tee D, Chinnaratha MA. Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: A systematic review and meta-analysis. Dig Liver Dis 2021;53:1396-403. [PMID: 34373229 DOI: 10.1016/j.dld.2021.07.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 26 |
Ronca V, Barabino M, Santambrogio R, Opocher E, Hodson J, Bertolini E, Birocchi S, Piccolo G, Battezzati P, Cattaneo M, Podda GM. Impact of Platelet Count on Perioperative Bleeding in Patients With Cirrhosis Undergoing Surgical Treatments of Liver Cancer. Hepatol Commun 2021. [PMID: 34716696 DOI: 10.1002/hep4.1806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 27 |
Primignani M, Tosetti G, Tripodi A. Thrombopoietin receptor agonists before elective invasive procedures in cirrhotic patients with thrombocytopenia: ready to start? Dig Liver Dis 2021;53:1364-5. [PMID: 34210622 DOI: 10.1016/j.dld.2021.06.008] [Reference Citation Analysis]
|
| 28 |
Radaelli F, Hassan C, Buscarini E, Dinis-Ribeiro M, Fuccio L. Second-generation thrombopoietin receptor agonists: New players in the management of cirrhotic patients undergoing therapeutic endoscopy? Dig Liver Dis 2021;53:1362-3. [PMID: 34088596 DOI: 10.1016/j.dld.2021.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 29 |
Armstrong N, Büyükkaramikli N, Penton H, Riemsma R, Wetzelaer P, Huertas Carrera V, Swift S, Drachen T, Raatz H, Ryder S, Shah D, Buksnys T, Worthy G, Duffy S, Al M, Kleijnen J. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis. Health Technol Assess 2020;24:1-220. [PMID: 33108266 DOI: 10.3310/hta24510] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 30 |
Sano Y, Morimoto M, Kobayashi S, Ueno M, Fukushima T, Asama H, Kawano K, Nagashima S, Tanaka S, Ohkawa S, Maeda S. Repeated Lusutrombopag Treatment for Thrombocytopenia in Patients with Chronic Liver Disease. Digestion 2021;102:654-62. [PMID: 32841939 DOI: 10.1159/000509852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Deng J, Hu H, Huang F, Huang C, Huang Q, Wang L, Wu A, Yang J, Qin D, Zou W, Wu J. Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial. Front Pharmacol 2021;12:704093. [PMID: 34393785 DOI: 10.3389/fphar.2021.704093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 32 |
Desai S, Subramanian A. Thrombocytopenia in Chronic Liver Disease: Challenges and Treatment Strategies. Cureus 2021;13:e16342. [PMID: 34277309 DOI: 10.7759/cureus.16342] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 33 |
Kawata Y, Endou M, Isozaki Y, Kitamura T, Fukushima Y, Sato T. Three cases of patients with chronic liver disease complicated by thrombocytopenia who were treated with lusutrombopag before tooth extraction. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology 2021;33:463-6. [DOI: 10.1016/j.ajoms.2021.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 34 |
Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 2021;51:725-49. [PMID: 34228859 DOI: 10.1111/hepr.13678] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 26.0] [Reference Citation Analysis]
|
| 35 |
Miki N, Inoue S, Shibahara H, Kurazono K, Perard R, Tateishi R. A cost-effectiveness analysis of lusutrombopag for thrombocytopenia in patients with chronic liver disease in Japan. JGH Open 2021;5:879-87. [PMID: 34386595 DOI: 10.1002/jgh3.12597] [Reference Citation Analysis]
|
| 36 |
Gilreath J, Lo M, Bubalo J. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists. Drugs 2021;81:1285-305. [PMID: 34160821 DOI: 10.1007/s40265-021-01553-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 37 |
Ballantine A, Martin D, Thakrar SV. The coagulopathy of liver disease: a shift in thinking. Br J Hosp Med (Lond) 2021;82:1-9. [PMID: 34191571 DOI: 10.12968/hmed.2021.0111] [Reference Citation Analysis]
|
| 38 |
Giannini EG, Kano T, Ochiai T, Bentley R, Shrestha P, Afdhal N. Bleeding events in lusutrombopag-treated thrombocytopenic patients. Eur J Clin Invest 2021;51:e13503. [PMID: 33523482 DOI: 10.1111/eci.13503] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 39 |
Alvaro D, Caporaso N, Giannini EG, Iacobellis A, Morelli M, Toniutto P, Violi F; PReBRiC (Procedure-Related Bleeding Risk in Cirrhosis) group. Procedure-related bleeding risk in patients with cirrhosis and severe thrombocytopenia. Eur J Clin Invest 2021;51:e13508. [PMID: 33539542 DOI: 10.1111/eci.13508] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 40 |
Lim MY, Gilreath JA. Periprocedural use of avatrombopag for neurosurgical interventions: a strategy to avoid platelet utilization. Blood Adv 2020;4:4438-41. [PMID: 32936905 DOI: 10.1182/bloodadvances.2020003045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 41 |
Wada N, Uojima H, Satoh T, Okina S, Iwasaki S, Shao X, Takiguchi H, Arase Y, Itokawa N, Atsukawa M, Miyazaki K, Hidaka H, Kako M, Kagawa T, Iwakiri K, Horie R, Suzuki T, Koizumi W. Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease. Dig Dis 2021;39:234-42. [PMID: 32759604 DOI: 10.1159/000510692] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 42 |
Scharf RE. Thrombocytopenia and Hemostatic Changes in Acute and Chronic Liver Disease: Pathophysiology, Clinical and Laboratory Features, and Management. J Clin Med 2021;10:1530. [PMID: 33917431 DOI: 10.3390/jcm10071530] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 43 |
Nishida Y, Kawaoka T, Imamura M, Namba M, Fujii Y, Uchikawa S, Ohya K, Daijo K, Teraoka Y, Morio K, Fujino H, Nakahara T, Yamauchi M, Hiramatsu A, Tsuge M, Aikata H, Takahashi S, Hayes CN, Fukuhara T, Tsuji K, Arataki K, Nagaoki Y, Aisaka Y, Kamada K, Kodama H, Chayama K. Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures. Intern Med 2021;60:829-37. [PMID: 33087674 DOI: 10.2169/internalmedicine.5930-20] [Reference Citation Analysis]
|
| 44 |
Yoshikawa Y, Kawaoka T, Andou Y, Kosaka Y, Suehiro Y, Uchikawa S, Nishida Y, Morio K, Nakahara T, Murakami E, Yamauchi M, Hiramatsu A, Imamura M, Aikata H, Chayama K. A case of successful repeated lusutrombopag administration for thrombocytopenia in a patient with cirrhosis requiring multiple invasive procedures. Acta hepatologica Japonica 2021;62:136-143. [DOI: 10.2957/kanzo.62.136] [Reference Citation Analysis]
|
| 45 |
Brown RS Jr, Imawari M, Izumi N, Osaki Y, Bentley R, Ochiai T, Kano T, Peck-Radosavljevic M. Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag. JHEP Rep 2021;3:100228. [PMID: 33644726 DOI: 10.1016/j.jhepr.2021.100228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 46 |
Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 2021;56:593-619. [PMID: 34231046 DOI: 10.1007/s00535-021-01788-x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 34.5] [Reference Citation Analysis]
|
| 47 |
Nomoto H, Morimoto N, Miura K, Watanabe S, Takaoka Y, Maeda H, Sasaki T, Koyashiki Y, Kurata H, Numao N, Isoda N, Yamamoto H. Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study. BMC Gastroenterol 2020;20:427. [PMID: 33317473 DOI: 10.1186/s12876-020-01573-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 48 |
Singh AD, Shalimar. Use of Blood Products and Drugs Before Procedures in Patients With Cirrhosis. Clin Liver Dis (Hoboken) 2020;16:153-7. [PMID: 33163168 DOI: 10.1002/cld.906] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 49 |
Numata K, Tanaka K, Katsube T, Ochiai T, Fukuhara T, Kano T, Osaki Y, Izumi N, Imawari M. Is platelet monitoring during 7-day lusutrombopag treatment necessary in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures? A phase IIIb open-label study. Hepatol Res 2020;50:1141-50. [PMID: 32609920 DOI: 10.1111/hepr.13544] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 50 |
Dieterich DT, Bernstein D, Flamm S, Pockros PJ, Reau N. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States. Aliment Pharmacol Ther 2020;52:1311-22. [PMID: 32813292 DOI: 10.1111/apt.16044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 51 |
Alkhouri N, Imawari M, Izumi N, Osaki Y, Ochiai T, Kano T, Bentley R, Trevisani F. Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2020;18:2600-2608.e1. [PMID: 32205226 DOI: 10.1016/j.cgh.2020.03.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 52 |
Kamezaki H, Naito T, Sekine Y, Maeda T, Senoo J, Sakamoto D. Lusutrombopag administration is effective for the hemostasis of intractable gastric antral vascular ectasia in a patient with liver cirrhosis. Acta hepatologica Japonica 2020;61:520-526. [DOI: 10.2957/kanzo.61.520] [Reference Citation Analysis]
|
| 53 |
Katsube T, Shimizu R, Fukuhara T, Kano T, Wajima T. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures. Clin Pharmacokinet 2019;58:1469-82. [PMID: 31055790 DOI: 10.1007/s40262-019-00770-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 54 |
Furuichi Y, Takeuchi H, Yoshimasu Y, Kasai Y, Abe M, Itoi T. Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching. Hepatol Res 2020;50:1062-70. [PMID: 32510789 DOI: 10.1111/hepr.13530] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 55 |
Khemichian S, Terrault NA. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease. Semin Thromb Hemost. 2020;46:682-692. [PMID: 32820479 DOI: 10.1055/s-0040-1715451] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 56 |
Nilles KM, Flamm SL. Thrombocytopenia in Chronic Liver Disease: New Management Strategies. Clin Liver Dis 2020;24:437-51. [PMID: 32620282 DOI: 10.1016/j.cld.2020.04.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 57 |
Saab S, Bernstein D, Hassanein T, Kugelmas M, Kwo P. Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure. J Clin Gastroenterol 2020;54:503-11. [PMID: 32195771 DOI: 10.1097/MCG.0000000000001338] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 58 |
Qureshi K, Bonder A. Thrombopoietin-receptor agonists in perioperative treatment of patients with chronic liver disease. World J Meta-Anal 2020; 8(3): 220-232 [DOI: 10.13105/wjma.v8.i3.220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 59 |
van Dievoet MA, Eeckhoudt S, Stephenne X. Primary Hemostasis in Chronic Liver Disease and Cirrhosis: What Did We Learn over the Past Decade? Int J Mol Sci 2020;21:E3294. [PMID: 32384725 DOI: 10.3390/ijms21093294] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 60 |
Shirley M, McCafferty EH, Blair HA. Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure. Drugs 2019;79:1689-95. [PMID: 31529283 DOI: 10.1007/s40265-019-01197-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 61 |
Lange NW, Salerno DM, Berger K, Cushing MM, Brown RS Jr. Management of Hepatic Coagulopathy in Bleeding and Nonbleeding Patients: An Evidence-Based Review. J Intensive Care Med 2021;36:524-41. [PMID: 32079443 DOI: 10.1177/0885066620903027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 62 |
Hirooka M, Ochi H, Hiraoka A, Koizumi Y, Tanaka T, Sunago K, Yukimoto A, Imai Y, Watanabe T, Yoshida O, Abe M, Joko K, Michitaka K, Hiasa Y. Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease. J Gastroenterol Hepatol 2020;35:299-304. [PMID: 31318996 DOI: 10.1111/jgh.14786] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 63 |
Moore AH. Thrombocytopenia in Cirrhosis: A Review of Pathophysiology and Management Options. Clin Liver Dis (Hoboken) 2019;14:183-6. [PMID: 31879561 DOI: 10.1002/cld.860] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 64 |
Peck-Radosavljevic M, Simon K, Iacobellis A, Hassanein T, Kayali Z, Tran A, Makara M, Ben Ari Z, Braun M, Mitrut P, Yang SS, Akdogan M, Pirisi M, Duggal A, Ochiai T, Motomiya T, Kano T, Nagata T, Afdhal N. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2). Hepatology 2019;70:1336-48. [PMID: 30762895 DOI: 10.1002/hep.30561] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 22.5] [Reference Citation Analysis]
|
| 65 |
Sasaki R, Shiino C, Imawari M, Bentley R, Cai B, Yoshida M, Afdhal N. Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance. Hepatol Res 2019;49:1169-81. [PMID: 31228221 DOI: 10.1111/hepr.13392] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 66 |
Saab S, Brown RS Jr. Management of Thrombocytopenia in Patients with Chronic Liver Disease. Dig Dis Sci 2019;64:2757-68. [PMID: 31011942 DOI: 10.1007/s10620-019-05615-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 67 |
Nilles KM, Caldwell SH, Flamm SL. Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists. Hepatol Commun 2019;3:1423-34. [PMID: 31701067 DOI: 10.1002/hep4.1423] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 68 |
Katsube T, Wajima T, Fukuhara T, Kano T. Effects of Food and Calcium Carbonate on the Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist. Clin Ther 2019;41:1747-1754.e2. [PMID: 31303281 DOI: 10.1016/j.clinthera.2019.06.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 69 |
Bankston PC, Al-Horani RA. New small molecule drugs for thrombocytopenia: chemical, pharmacological, and therapeutic use considerations. Int J Mol Sci. 2019;20:3013. [PMID: 31226783 DOI: 10.3390/ijms20123013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 70 |
Ryan L. Procedural Risk of Bleeding: Does the Management of Thrombocytopenia in Chronic Liver Disease Patients Make a Difference? A Debate. EMJ Hepatol 2019. [DOI: 10.33590/emjhepatol/10313853] [Reference Citation Analysis]
|
| 71 |
Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol 2019;10:2040620719841735. [PMID: 31007886 DOI: 10.1177/2040620719841735] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 72 |
Uojima H, Arase Y, Itokawa N, Atsukawa M, Satoh T, Miyazaki K, Hidaka H, Sung JH, Kako M, Tsuruya K, Kagawa T, Iwakiri K, Horie R, Koizumi W. Relationship between response to lusutrombopag and splenic volume. World J Gastroenterol 2018; 24(46): 5271-5279 [PMID: 30581275 DOI: 10.3748/wjg.v24.i46.5271] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
|
